Cadila Healthcare is currently trading at Rs 767.20, up by 1.95 points or 0.25% from its previous closing of Rs 765.25 on the BSE.
The scrip opened at Rs 767.75 and has touched a high and low of Rs 770.00 and Rs 760.85 respectively. So far 1036 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 5 has touched a 52 week high of Rs 964.00 on 12-Sep-2012 and a 52 week low of Rs 683.50 on 16-Mar-2012.
Last one week high and low of the scrip stood at Rs 785.60 and Rs 758.05 respectively. The current market cap of the company is Rs 15708.31 crore.
The promoters holding in the company stood at 74.79% while Institutions and Non-Institutions held 16.32% and 8.89% respectively.
Zydus Cadila has received tentative approval from USFDA for Doxepin Hcl tablets in the strengths of 3 mg and 6 mg. The estimated sales in 2012 as per IMS for Doxepin Hcl, which falls in the neuropsychiatry segment was $15.5 million. It is scheduled to be launched in June 2020 upon patent expiry.
The group now has 77 approvals and has so far filed 172 ANDAs since the commencement of the filing process in FY 2003-04.
The flagship company of Zydus Cadila Group, focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1806.75 |
Dr. Reddys Lab | 1342.90 |
Cipla | 1472.00 |
Lupin | 2156.35 |
Zydus Lifesciences | 968.80 |
View more.. |